US20100191103A1 - Apparatus and method for surgical bypass of aqueous humor - Google Patents

Abstract

The invention provides minimally invasive microsurgical tools and methods to form an aqueous humor shunt or bypass for the treatment of glaucoma. The invention enables surgical creation of a tissue tract (7) within the tissues of the eye to directly connect a source of aqueous humor such as the anterior chamber (1), to an ocular vein (4). The tissue tract (7) from the vein (4) may be connected to any source of aqueous humor, including the anterior chamber (1) ), an aqueous collector channel, Schlemm's canal (2), or a drainage bleb. Since the aqueous humor passes directly into the venous system, the normal drainage process for aqueous humor is restored. Furthermore, the invention discloses devices and materials that can be implanted in the tissue tract to maintain the tissue space and fluid flow.

Description

CROSS-REFERENCE TO RELATED APPLICATION
• This application claims priority of U.S. Provisional Patent Application No. 60/411,668 (Attorney Docket No. ISC1P003P), filed 17 Sep. 2002, which application is incorporated herein by reference in its entirety for all purposes.
BACKGROUND OF THE INVENTION
• Glaucoma is a disease condition of the eye in which increased intraocular pressure (IOP) is created by dysfunction in the drainage mechanism for the aqueous humor. Aqueous humor is produced within the eye in the ciliary body and flows within the anterior region of the eye. The aqueous humor normally flows through a network of tissues at the interior angle of the anterior chamber, named the trabecular meshwork and subsequently into a circular drainage space named Schlemm's canal. The aqueous humor continues its drainage path into collector channels and finally into aqueous veins to enter the venous system.
• Typically in open angle glaucoma, the pathway for aqueous humor becomes narrowed or occluded, increasing IOP and resulting in gradual nerve damage and loss of vision. Such conditions are usually treated by topical drugs in the form of eye drops, but may result in surgical treatment if drug treatment becomes ineffective or if patient compliance is an issue. Traditional glaucoma surgery, such as trabeculotomy or trabeculectomy, involves dissection of the eye and the forming of new holes through the trabecular meshwork portion of the drainage pathway. The fluid is channeled to a reservoir formed under the conjunctiva known as a bleb. While blebs are effective in removing the aqueous humor, bleb complications present the highest incidence of post-surgical complications due to irritation and infection.
• A new class of surgical procedures aims to approach treatment of the ocular drainage system from the scleral tissues without penetrating the interior chamber of the eye. These procedures are termed “non-penetrating” surgery and involve careful surgical dissection of the scleral tissues to access the tissues involved with ocular drainage. Deep sclerectomy is a form of this type of procedure in which a portion of intrascleral tissue is removed nearly to Descemet's membrane to allow significant aqueous flow from the anterior chamber to a bleb. Viscocanalostomy is another non-penetrating procedure, which increases the flow of aqueous humor form the anterior chamber into a surgically created intrascleral lake. Although non-penetrating procedures present fewer direct complications than traditional surgeries, most of the procedures still require the surgical dissection of ocular tissues and a high level of surgical skill.
• Various approaches and devices for glaucoma surgery involving the rerouting of aqueous humor have been described in the art. One approach involves the shunting of aqueous humor through a tube in the anterior chamber into a reservoir implanted on the surface of the eye. See Mendez U.S. Pat. No. 4,428,746, White U.S. Pat. No. 4,554,918, Molteno U.S. Pat. No. 4,750,901, Ahmed U.S. Pat. Nos. 5,071,408, 5,411,473, 5,616,118, 5,681,275, 5,785,674, 6,261,256, Baerveldt, et al. U.S. Pat. Nos. 5,178,604, 5,397,300, 5,558,629, 6,050,970, Speckman U.S. Pat. No. 5,338,291, Memmen U.S. Pat. No. 5,370,607, Jacob U.S. Pat. No. 5,882,327, Odrich U.S. Pat. No. 6,41,666. A similar approach is to shunt the aqueous humor through a tube placed in the anterior chamber into a bleb on the surface of the eye. See Worst U.S. Pat. No. 5,180,362, Suson U.S. Pat. No. 6,508,779, Wilcox WO 02/32343.
• Another approach described in the art is the shunting of aqueous humor from the anterior chamber to the tear film of the eye. See Ungerleider U.S. Pat. Nos. 4,936,825; 5,372,577; Wandel U.S. Pat. No. 5,807,302; Brown U.S. Pat. No. 6,595,945.
• Another approach described in the art is placing a shunt for aqueous humor through the trabecular meshwork to connect the anterior chamber and Schlemm's canal. See Lynch et al. U.S. Pat. No. 6,450,984, Hill U.S. Pat. No. 6,533,768, WO 01/78656, and Gharib et al. US 2002 0165478.
SUMMARY OF THE INVENTION
• The invention provides an apparatus for creating a tract within the scleral tissues of an eye comprising an elongated body portion shaped to create a tract which forms a path for flow of aqueous humor into an ocular vein. The elongated body portion has a proximal end and a distal end. The distal end may comprise a mechanically cutting tip or an energy source to ablate tissue. The distal end may be visible by medical imaging methods such as ultra sound, or optical coherence topography or visible under direct observation by an optical beacon at the tip. The apparatus may additionally accommodate a space-maintaining material for placement within the tract, such as hyaluronic acid or a cell proliferation inhibitor. These space-maintaining materials may also comprise a stent device made of hyaluronic acid, nickel, titanium alloy or other material.
• The invention also provides a method for creating a path for flow of aqueous humor of the eye into an ocular vein comprising;
• a. inserting an apparatus to form a tissue opening into an ocular vein on the anterior portion of the eye;
• b. directing the apparatus to create a tract from the vein to a source of aqueous humor,
• c. removing the apparatus;
• d. closing the tissue opening while retaining flow through the tract between the vein and the source.
• In another embodiment of the method the path is created by
• a. inserting the apparatus through a tissue opening in the eye into a source of aqueous humor;
• b. directing the apparatus to create a tract from the source into an ocular vein;
• c. removing the apparatus while retaining flow through the tract between the vein and the source; and
• d. optionally closing the tissue opening.
• The source of aqueous humor typically will comprise the anterior chamber, Schlemm's canal, the collector channel or a bleb.
BRIEF DESCRIPTION OF THE DRAWINGS
• FIG. 1. Sectional view of the anterior portion of the human eye.
• FIG. 2. Cross-sectional view of the drainage system in the human eye.
• FIG. 3. Cross-sectional view of the drainage system in the human eye showing a microsurgical tool and tissue tract from an episcleral vein to the anterior chamber.
• FIG. 4. Cross-sectional view of the drainage system in the human eye showing tissue tract from an episcleral vein to Schlemm's canal.
• FIG. 5. Cross-sectional view of the of an embodiment of the invention comprising a microcannula assembly.
• FIG. 6. View of an embodiment of a microcannula assembly incorporating fiber optic core for transmission of energy from a source.
• FIG. 7A. View of an embodiment of the invention comprising tube-stent devices.
• FIG. 7B. View of a stent device comprising alternating filament loops.
• FIG. 8A. Sectional view of the anterior portion of the human eye showing bypass implant comprising shape memory material incorporating a reduced diameter segment to maintain flow control at a minimum level.
• FIG. 8B. Sectional view of the anterior portion of the human eye showing laser energy being applied externally to increase the diameter of the shape memory bypass implant.
• FIG. 9. Cross-sectional view of microcannula assembly incorporating a detachable tube stent as the distal sheath of the assembly.
• FIG. 10A. Sectional view of the anterior portion of the human eye showing detachable tube stent assembly creating tract from an episcleral vein to the anterior chamber.
• FIG. 10B. Sectional view of the anterior portion of the human eye showing tube stent in place after removal of the cannula assembly.
DESCRIPTION OF INVENTION
• The present invention to provide minimally invasive microsurgical tools and methods, which enable surgical creation of a tissue tract within the tissues of the eye to directly connect a source of aqueous humor such as the anterior chamber, to an ocular vein, thereby forming a shunt or bypass for aqueous humor. The aqueous veins, into which aqueous humor normally drains, are good candidates for this procedure, however the invention is not limited to these specific vessels. Furthermore, the tissue tract from the vein may be connected to any source of aqueous humor, including the anterior chamber, an aqueous collector channel, Schlemm's canal, or a drainage bleb. Since the aqueous humor passes directly into the venous system, the normal drainage process for aqueous humor is restored. The tools and methods effectively bypass the small anatomical structures of the drainage system, such as the trabecular meshwork, Schlemm's canal and the collector channels, which have been identified with the mechanism of glaucoma. Furthermore, the invention describes devices and materials that can be implanted in the tract to maintain the tissue space and fluid flow post operatively.
• The invention comprises tools, materials and related methods to surgically create a bypass for aqueous humor.FIG. 1 shows a sectional view of the anterior portion of the human eye for reference. The invention involves the steps of: firstly, identifying acandidate vein4 on or within the eye of a living subject; secondly, inserting one or more tools into the eye to create a tissue tract in thesclera3, that connects the vein to a source of aqueous humor such as the anterior chamber of theeye1, or Schlemm'scanal2; thirdly, optionally inserting an implant or material to maintain the tract opening and fluid flow, and; lastly, closing the surgical access site as required. The tools and materials comprise the apparatus to create a tissue tract within scleral tissues of the eye such that the tract acts as a fluid path for aqueous humor to the vein.
• A magnified cross-sectional view of the drainage system of the human eye is shown inFIG. 2 for reference. Anepiscleral vein4 is identified suitable for creating the bypass. Candidate vessels can be found close to the surface of the eye, such as but not limited to, conjunctiva veins, anterior ciliary veins, and episcleral veins. Surface vessels can be directly visualized and accessed while subconjunctival vessels may require a small incision in the conjunctiva for access. Subsurface vessels such ascollector channels5 andaqueous veins6 can be identified by high-resolution medical imaging methods such as high frequency ultrasound (HFU) or optical coherence topography (OCT). The use of medical imaging is preferred in that veins which are in the most surgically desired location, can be selected. Vessels which are angled toward theanterior chamber1, or Schlemm'scanal2, and having appropriate dimensions and minimal tortuosity, can be identified as candidates for bypass. The use of an ultrasound or optical contrast agent, either delivered directly to the candidate vein or systemically to the subject, will facilitate vein identification. Doppler imaging can be used to assist identification of candidate blood vessels. Pressure changes applied to the anterior chamber will also facilitate vein identification and selection by distinguishing vessels with the most direct connection to the aqueous drainage system. In some situations the blood/aqueous interface can be seen in episcleral veins. Changes in pressure in the chamber will cause this interface to move forward and backward within the vein. Furthermore, pressure changes can result in a change of the apparent vein diameter, which can be directly observed.
• Cross-sectional views of the drainage system of the human eye with a surgically created tissue tract are shown inFIGS. 3 and 4 for reference. The use of HFU or OCT imaging is desired to determine the optimal placement of thetissue tract7, from the candidate vein to theanterior chamber1, or if desired, to a collector channel, Schlemm'scanal2, or an existing bleb. When forming aconnection9 of a vein to the anterior chamber, any region of the anterior chamber in proximity to the vein may be used including the area at the anterior segment angle and the corneal-scleral junction. The surgeon may use imaging techniques to pre-plan the route of the surgery and to verify locations, direction and placement of themicrosurgical tool8, during the procedure. The method may comprise first access to avein4, and then creating atract7, toward and into a source of aqueous humor such as theanterior chamber1. Alternatively, the method may comprise access from the anterior chamber first, and then through the subsurface tissues to a vein. The advantage of such a method is that the tissue penetration may be accomplished through clear cornea, starting 180° from the bypass point and transversing through the anterior chamber. The microsurgical tool is placed at the correct site for penetration of the tissues through to the candidate vein. Small, clear corneal incisions are self-sealing and therefore do not require closure mechanisms. If the initial penetration of the tool into the eye is elsewhere, then the entry inscision may need to be closed after removal of the tool.
• The microsurgical tool may comprise an elongated tool, such as a microcannula, with a tip at one end which is directed into a vein. This may be a mechanically cutting tip such as a solid or hollow trocar-like member capable of creating a tunneled tract of controlled diameter through scleral tissues. In another embodiment, the tool may comprise a hollow tube with a sharpened distal edge used to core out a tissue tract. The removal of tissue may promote the subsequent stability of the tract and aid placement of an implant device into the channel. Referring toFIG. 5, the tool may comprise anouter sheath11 and inner member, with the outer sheath disposed axially about the inner member. The inner member may comprise atrocar10, solid rod, hollow rod or cylinder, needle, wire or optical fiber. The inner member may be designed to allow exchange during use to allow specific functions to be brought to the tip of the tool once it is located in tissue. The microcannula may be handled at its proximal end by a suitable accommodating mechanism such as luer fitting12.
• Referring toFIG. 6, an optical fiber inner member may be used to carry visible light to the tip of thefiber13, which may be disposed to reside at the tip of the sheath and hence may be used for direct visualization of the location of the tool through scleral tissues. In the case of an opaque outer sheath material, a cutout section or window near the distal tip of the sheath may be provided to visualize the optical fiber tip. The optical fiber may be fabricated from glass, fused silica, or plastic that is optically transparent to the wavelength of light used for visualization. The described optical beacon can provide an adjunct method of tracking the creation of the tract, aiding HFU or OCT imaging. Alternately, the optical fiber may be used to carry energy for tissue ablation such as laser energy, in order to create the tract. The tip may also accommodate transmission of radio frequency or thermal energy to ablate or coagulate tissue. Thefiber optic line14 is connected toenergy source15.
• The microsurgical tool is sized appropriate for access through small vessels and to create controlled diameter tissue tracts. Diameters from 50-500 microns are useful, and in particular diameters from 50-200 microns are preferred. Outer diameter of a sheath member may correspond to these ranges and may comprise a wall thickness between 10 and 100 microns. The microsurgical tool can comprise a flexible microcannula to allow the distal tip to be advanced within the vein toward a source of aqueous humor such as the anterior chamber. The microsurgical tool may be fabricated from structural materials such as metals including steel, titanium, and nickel-titanium alloys, structural polymers including polyimide, polyethylene, polyamide, polypropylene, polystyrene, polymethylmethacrylate, polytetrafluoroethylene, and polysulfone. Several tools with different material composition and design may be used sequentially in the surgical procedure. For example, one tool may be used to access the vessel and exchanged with a tool to create the scleral tissue tract. Alternatively, different types of inner members such as for cutting or light conduction may be used interchangeably within an outer sheath.
• The tool will accommodate features for orientation of the tract identified and controlled by the clinical practitioner. The use of medical imaging to coordinate or verify the position and orientation of the tract aids accuracy and precision of tract placement. Tools which are in the field of view of the imaging system allow for identification of the tool's position while minimizing the creation of artifacts into the image. Selection of tool material and/or the use of contrast markers can provide the desired imaging properties for the tools.
• The tract created may optionally be filled with a material to help maintain the patency and fluid flow of the tract. Such materials may comprise an anti-fibrotic material, anti-thrombotic agent, space maintaining material, tube-like stent or similar device to assure that the drainage tract remains patent. Anti-fibrotic materials such as hyaluronic acid and cellular proliferation inhibitors such as methotrexate, sirolimus, and paclitaxel, may be applied or released from a device within the tract. Anti-thrombotic agents such as heparin and tissue plasminogen activator may also be applied or released from a device within the tract. Such materials may be in the form of microspheres, microparticles, microfibers, open-or closed-cell matrices, foams, gels and tubes, which may be designed to change their configuration in-situ after implantation. The materials may comprise degradable materials such as hyaluronic acid, collagen , glycosoaminoglycans and degradable synthetic polymers. The materials may also comprise non-degradable materials with biocompatibility suitable for implant use including metals such as steel, titanium, and nickel-titanium alloys, and polymers such as polytetrafluoroethylene, polymethylmethacrylate, polyimide, polyethylene, polypropylene and polysulfone.
• A tubular stent-like device may be placed within the tract to enlarge the tract diameter or provide stabilization through mechanical means. Referring toFIG. 7a, there are examples shown of asimple tube16 and afenestrated tube17. The outer sheath of the microsurgical tool may comprise a tube-stent, and can be left behind after the tool core is removed. Referring toFIG. 9, there is shown such a microcannula assembly comprising atrocar tip core10, thedetachable stent22, drivingcannula23, and handle24. The tube-stent may be pre-sized based on pre-surgical imaging or may be designed to be cut to size prior to or after implantation. The venous end of the tube-stent may be implanted to reside in the vein or further advanced to reside in a collector channel. The tube-stent may reside in the entire tissue tract between the vein and the aqueous humor source, or a portion of the tract. Several discrete tube-stents may also be used in stabilizing the tissue tract.
• The diameter of the tube-stent may be designed to allow expansion in-situ, for example, by hydraulic pressure or thermal energy, or through the use of shape memory materials for construction of the tube-stent. Referring toFIG. 8b, alaser20 is used to increase the diameter of ashape memory implant21. For long-term stability, preferred are tube-stents designed to be conformable to the tissue tract and that do not create mechanical loads on the tissue other than for dilation of the tract. Mechanical features of the tube-stent such as tissue interfacing porosity may be incorporated to aid retention. Tube-like stents may be comprised of permanent or biodegradable materials. Suitable materials include metals such as steel, titanium and nickel titanium alloys, and biocompatible polymers such as hyaluronic acid, collagen, glycosoaminoglycans, polylactic acid, polyglycolic acid, polytetrafluoroethylene, polymethylmethacrylate, polyimide, polyethylene, polypropylene and polysulfone
• Furthermore, the tube-stent device can also have a design to provide a controlled amount of flow restriction that would limit retrograde flow of blood. Devices with different flow resistance may be fabricated and chosen for optimization of aqueous flow by the practitioner. Referring toFIG. 8a,a shape memory stent incorporating areduced diameter segment19 connects theanterior chamber2 with anepiscleral vein4 viaentry point9. A valve may be incorporated into the tube stent to limit retrograde flow or to set a threshold pressure for flow. In another embodiment, the flow characteristics of the tube-stent may be varied after the procedure upon examination of the patient's IOP. Various energy sources such as laser light, RF or microwave may be directed at a portion of the implant to dilate or contract discrete segments to control flow. A photoreactive polymer or a pre-stressed polymer similar to heat shrink tubing may be employed to perform this function.
• In a similar embodiment, the stent-like device may comprise a series of filaments or wires. Referring toFIG. 7b, the device may be formed as a woven tube or a series offilament loops18. The filament loops may be attached to each other in an alternating, or “zigzag” pattern, or may be attached to a linear member along one axis. The loops may be disposed at an angle to the axis, and be sufficiently flexible to maintain the tract opening without creating undue stress upon the surrounding tissues. Such an embodiment allows for the stent device to conform to changes in diameter or direction of the tract.
• The invention also provides methods to surgically create an aqueous bypass in the eye. The following methods are provided as explanatory and do not constitute the entire scope of methods which may be used in conjunction with the microsurgical tools described herein. Referring toFIGS. 10aand10b, in a first example, the surgeon will visually identify acandidate vein4 on or about the surface of the eye. Using high resolution imaging techniques, a pathway from a target point along the axis of the vein to the desired endpoint, such as theanterior chamber2, is mapped. A surgical tool comprising ahandle24,tube stent sheath22, and trocar is used. The trocar has a distal point configured to pierce the tissues. The tube-stent will be of correct length to connect the chamber and vein. The vein is cannulated with the tool at the target point, and the tool oriented in the angle and direction that was plotted from the imaging session. The tool is advanced along the pathway until the tip is seen penetrating the anterior chamber atentry point9, preferably above the iris. The trocar inner member and the tool are removed, leaving the tube-stent22 behind. Alternatively, a syringe containing an antifibrotic hydrogel can be attached to the proximal end of the sheath. The hydrogel is applied into the tract at the same time that the tool, including the sheath, is being withdrawn, to aid in maintaining the tract. The access site is then sealed by any requisite surgical method.
• In another example, an episcleral vein is located by visualization through a surgical microscope. A target point is designated along the vein, at a distal point of sufficient diameter to accept the incoming microsurgical tool. An entry point is determined along the corneal limbus approximately 180° away from the candidate vein. A gonio lens is used to visually inspect the anterior angle at the bypass site to choose a target entry point to connect to the vein. The microsurgical tool in this instance comprises a fiber optic inner member with a trocar like distal tip and an outer member comprising a tube-stent of the correct length to connect the chamber and vein. The tool is advanced through the clear cornea at the entry point and advanced across the anterior chamber to the tissue entry point. The tool is then advanced through the tissues guided toward the candidate vein by visualization of the beacon tip of the tool. The tool is advanced until the distal tip enters the vein and then continued until a sufficient portion of the tube stent distal end is within the vessel to maintain flow. If sized correctly, the proximal end of the tube stent will now reside just within the anterior chamber. The tool is withdrawn, leaving the tube stent behind. The entry point may be surgically closed or allowed to self-seal.
• The procedure may also be performed on more than one venous site per eye as may be required to provide adequate drainage. In practice, the procedure may be performed on one site, and the patient's IOP monitored post-surgically. If more pressure reduction is required, then a subsequent procedure may be performed at another target site. Multiple drainage paths can thereby be created.

Claims (23)

1. An apparatus for creating a tract within the scleral tissues of an eye comprising:

an elongated body portion shaped to create said tract wherein said tract forms a path for flow of aqueous humor into an ocular vein.

2. The apparatus ofclaim 1 wherein said body portion comprises a proximal end and distal end.

3. The apparatus ofclaim 2 wherein said body portion has an outer diameter in the range of 50 to 500 microns.

4. The apparatus ofclaim 2 wherein said body portion comprises a flexible microcannula.

5. The apparatus ofclaim 2 wherein said distal end comprises a mechanical cutting tip.

6. The apparatus ofclaim 2 where in said distal end comprises an energy source to ablate tissue.

7. The apparatus ofclaim 6 wherein said energy comprises laser light, radio frequency energy, or thermal energy.

8. The apparatus ofclaim 2 where said distal end is visible by medical imaging.

9. The apparatus ofclaim 8 wherein medical imaging comprises ultrasound or optical coherence tomography.

10. The apparatus ofclaim 2 wherein said distal end comprises an optical beacon visible under direct observation through scleral tissues.

11. The apparatus ofclaim 2 wherein said body portion comprises an outer sheath and an inner member.

12. The apparatus ofclaim 11 wherein said inner member is removable during use from said outer sheath.

13. The apparatus ofclaim 1 which additionally comprises a space maintaining material placeable within said tract.

14. The apparatus ofclaim 13 wherein said space maintaining material comprises hyaluronic acid.

15. The apparatus ofclaim 13 wherein said space maintaining material comprises a cellular proliferation inhibitor.

16. The apparatus ofclaim 15, wherein said cellular proliferation inhibitor comprises methotrexate, paclitaxel, or sirolimus.

17. The apparatus ofclaim 13, wherein said space maintaining material comprises an anti-thrombotic agent.

18. The apparatus ofclaim 17 wherein said anti-thrombotic agent comprises heparin or tissue plasminogen activator.

19. The apparatus ofclaim 13 wherein said material comprises a stent device.

20. The apparatus ofclaim 19 wherein said device comprises hyaluronic acid.

21. The apparatus ofclaim 19 wherein said device comprises a nickel titanium alloy.

22. The apparatus ofclaim 19 wherein said device is changeable in situ from a first configuration to a second configuration.

23-30. (canceled)

Images